Okudaira Y, Sugimachi K, Inokuchi K, Kai H, Kuwano H, Matsuura H
Jpn J Surg. 1982;12(4):249-56. doi: 10.1007/BF02469556.
Two groups of patients with esophageal carcinoma were studied retrospectively: Group I as controls, included 50 patients who underwent esophageal resection mainly combined with preoperative radiation therapy during the period from 1965 to 1971; and Group 2 included 83 patients who were given the same treatment plus post-operative radiation and adjuvant postoperative long-term cancer immunochemotherapy during the period from 1972-1979. The one, two and five-year survival rates were 32.0, 14.0 and 12.0 per cent in Group 1, and 55.4, 35.8 and 21.5 per cent in Group 2 respectively. There were significant differences in one-year (p less than 0.02) and two-year (p less than 0.05) survival rates between the two groups. We also found that adjuvant therapy was effective in patients with no lymph node metastasis, while it was less effective in those with lymph node metastases.
第一组作为对照组，包括1965年至1971年期间接受食管切除术且主要联合术前放射治疗的50例患者；第二组包括1972年至1979年期间接受相同治疗并加用术后放疗及辅助性术后长期癌症免疫化疗的83例患者。第一组的1年、2年和5年生存率分别为32.0%、14.0%和12.0%，第二组分别为55.4%、35.8%和21.5%。两组之间的1年生存率（p<0.02）和2年生存率（p<0.05）存在显著差异。我们还发现，辅助治疗对无淋巴结转移的患者有效，而对有淋巴结转移的患者效果较差。
